Glycogene Discovery Service in Breast Cancer

Glycogene Discovery Service in Breast Cancer

Breast Cancer and Glycosylation

Breast cancer is a universal disease in women worldwide and the leading cause of cancer fatality rate among women. Therefore, it is imminent to find potential biomarkers and functional targets that can be applied to individualized precision therapy to reduce mortality. Glucose metabolism disorder is a universal feature of cancer. However, long non-coding RNA (lncRNAs) may play an important role in this process. A few critical enzymes, such as hexokinase, pyruvate kinase M, and lactate dehydrogenase, that affect glycolysis, oxidative phosphorylation, and pentose phosphate pathway were used to promote the metastasis and invasion of cancer cells by lncRNAs. Unusual glycosylation positively promotes tumor progression and is a biomarker of cancer. Clinically, specific glycosylation of glycoproteins is defined as a tumor biomarker.

Fig.1 A co-expression network of glucose metabolism-related lncRNAs and glucose metabolism-related genes. (Xu, et al., 2023)Fig.1 A co-expression network of glucose metabolism-related lncRNAs and glucose metabolism-related genes. (Xu, et al., 2023)

Glycogene Discovery Service in Breast Cancer

At CD BioGlyco, our team consists of specialized chemical scientists and engineers with a wealth of experience and in-depth knowledge. Our Glycogenomics Platform combines advanced methods and techniques that are used to custom glycogene discovery service in breast cancer. The services we provide include but are not limited to:

  • Discovery methods
    • Univariate Cox and Lasso regression analysis
      Identify prognostic glycogenes
    • The Single Sample Gene Set Enrichment
      Validate the expressions of a glycogene and its products.
    • Immunohistochemistry and western blotting
      Identify glucose metabolism-related genes.
    • Liquid chromatography-electrospray ionization MS (LC/ESI-MS), matrix-assisted laser desorption/ionization-time of flight MS (MALDI-TOF-MS)
      To characterize glycan.
  • Summary of glycogenes involved in breast cancer
    • CA153 (carbohydrate antigen 153)
    • CEA (carcinoembryonic antigen)
    • CA125 (carbohydrate antigen 125)
    • CA549 (carbohydrate antigen 549)
    • Fer (ferritin)
    • β-HCG (specific β-human chorionic gonadotropin)
    • BRCA1 (breast CAncer gene 1)
    • BRCA2 (breast CAncer gene 2)

Fig.2 Glycogene discovery in breast cancer. (CD BioGlyco)Fig.2 Glycogene discovery in breast cancer. (CD BioGlyco)


  • A prognostic risk model based on the glucose metabolism-related lncRNAs which predict a clinical outcome in breast cancer.
  • Used as predictors and recurrence monitoring indicators in the management of breast cancer patients.
  • The principle of breast cancer formation may be clarified by identifying abnormal glycosylation of crucial proteins.


  • Advanced technology platform.
  • Fully custom-designed one-stop service.
  • Detailed after-sales service.
  • Combination of multiple advanced analysis platforms.

CD BioGlyco has enriched the Cancer Glycogene Discovery Service to cover our client's essential needs and we continue to conduct research and expand our service area to help our clients achieve their goals. Welcome to contact us for custom service. We look forward to your happy cooperation.


  1. Xu, J.L.; et al. Glucose metabolism and lncRNAs in breast cancer: sworn friend. Cancer Medicine. 2023, 12(4): 5137-5149.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.